ARTV

Artiva Biotherapeutics' stock (ARTV) has seen significant fluctuations, with a 181.88% increase over 12 months and an 87.50% year-to-date return, but a 26.75% decrease in the past month. Key events include the announcement of full-year 2025 financial results and business highlights on March 10, 2026, which included expectations for initial clinical response data for AlloNK in refractory rheumatoid arthritis in the first half of 2026 and an FDA interaction to discuss potential pivotal trial design. Artiva also provided an update on planned AlloNK data disclosures and development milestones for the remainder of 2026, including updated clinical data expected in the second half of 2026 from patients with refractory rheumatoid arthritis, Sjögren disease, and systemic sclerosis, and the initiation of a Phase 3 registrational randomized controlled trial for AlloNK plus rituximab in refractory RA. Additionally, an executive notified an intention to sell stock in September 2026, and the next earnings report is expected around November 11 or 18, 2026.